A temporal proteome dynamics study reveals the molecular basis of induced phenotypic resistance in Mycobacterium smegmatis at sub-lethal rifampicin concentrations
Open Access
- 6 March 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep43858
Abstract
In the last 40 years only one new antitubercular drug has been approved, whilst resistance to current drugs, including rifampicin, is spreading. Here, we used the model organism Mycobacterium smegmatis to study mechanisms of phenotypic mycobacterial resistance, employing quantitative mass spectrometry-based proteomics to investigate the temporal effects of sub-lethal concentrations of rifampicin on the mycobacterial proteome at time-points corresponding to early response, onset of bacteriostasis and early recovery. Across 18 samples, a total of 3,218 proteins were identified from 31,846 distinct peptides averaging 16,250 identified peptides per sample. We found evidence that two component signal transduction systems (e.g. MprA/MprB) play a major role during initial mycobacterial adaptive responses to sub-lethal rifampicin and that, after dampening an initial SOS response, the bacteria supress the DevR (DosR) regulon and also upregulate their transcriptional and translational machineries. Furthermore, we found a co-ordinated dysregulation in haeme and mycobactin synthesis. Finally, gradual upregulation of the M. smegmatis-specific rifampin ADP-ribosyl transferase was observed which, together with upregulation of transcriptional and translational machinery, likely explains recovery of normal growth. Overall, our data indicates that in mycobacteria, sub-lethal rifampicin triggers a concerted phenotypic response that contrasts significantly with that observed at higher antimicrobial doses.Keywords
This publication has 73 references indexed in Scilit:
- RpoS Plays a Central Role in the SOS Induction by Sub-Lethal Aminoglycoside Concentrations in Vibrio choleraePLOS Genetics, 2013
- β-lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelityNature Communications, 2013
- Bedaquiline: First FDA-approved tuberculosis drug in 40 yearsInternational Journal of Applied & Basic Medical Research, 2013
- Selection of resistance at lethal and non-lethal antibiotic concentrationsCurrent Opinion in Microbiology, 2012
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- How antibiotics kill bacteria: from targets to networksNature Reviews Microbiology, 2010
- Sublethal Antibiotic Treatment Leads to Multidrug Resistance via Radical-Induced MutagenesisMolecular Cell, 2010
- The DosR regulon of M. tuberculosis and antibacterial toleranceTuberculosis, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of ArrProceedings of the National Academy of Sciences, 2008